Physician profile
Anna Manasherov
NPI 1477138329
$562.06
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $454.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $178.48 | 2022 | |
| Merck Sharp & Dohme LLC | $111.25 | 2022 | |
| Lilly USA, LLC | $90.45 | 2021 | |
| Pfizer INC. | $59.27 | 2022 | |
| Sobi, INC | $39.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.73 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $22.66 | 2022 | |
| Dova Pharmaceuticals | $17.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.64 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Manasherov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.